Trial record 1 of 1 for:    nct01987999
Previous Study | Return to List | Next Study

Eradication of Prostate Cancer Using an Adenosine-5'-Triphosphate (ATP) Inhibitor

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01987999
Recruitment Status : Completed
First Posted : November 20, 2013
Last Update Posted : March 30, 2016
Information provided by (Responsible Party):
Optimal Health Research

Brief Summary:
The purpose of this study is to confirm the findings of an early study with prostate cancer and to expand our knowledge of treating prostate cancer using an Adenosine-5'-triphosphate(ATP)inhibitor.

Condition or disease Intervention/treatment Phase
Prostate Cancer Dietary Supplement: Acetogenins Phase 2

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 60 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase II Eradication of Prostate Cancer Using an Adenosine-5'-Triphosphate(ATP)Inhibitor.
Study Start Date : February 2013
Actual Primary Completion Date : December 2015
Actual Study Completion Date : December 2015

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Prostate Cancer
Drug Information available for: Adenosine

Arm Intervention/treatment
Experimental: Acetogenins
Acetogenins twice (BID) per day for 12 months
Dietary Supplement: Acetogenins

Primary Outcome Measures :
  1. Gleason Score [ Time Frame: 1 year ]
    A Gleason Score is obtained from the results of a transrectal needle biopsy of the prostate.

Secondary Outcome Measures :
  1. Prostate Specific Antigens (PSA) [ Time Frame: 1 year ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   40 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Clinical diagnosis of prostate cancer
  • Referred to the study by their treating physician

Exclusion Criteria:

- Any type of treatment before starting study

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01987999

Sponsors and Collaborators
Optimal Health Research
Principal Investigator: Steven Osguthorpe, ND Optimal Health Research

Responsible Party: Optimal Health Research Identifier: NCT01987999     History of Changes
Other Study ID Numbers: F-9892131
First Posted: November 20, 2013    Key Record Dates
Last Update Posted: March 30, 2016
Last Verified: March 2016

Additional relevant MeSH terms:
Prostatic Neoplasms
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
Genital Diseases, Male
Prostatic Diseases
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Arrhythmia Agents
Vasodilator Agents
Purinergic P1 Receptor Agonists
Purinergic Agonists
Purinergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action